1812TiP IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)

MLA

Rudin, C. M., et al. “1812TiP IDeate-Lung03: A Phase Ib/II Study of Ifinatamab Deruxtecan (I-DXd) plus Atezolizumab (Atezo) with or without Carboplatin (Carbo) as First-Line (1L) Induction or Maintenance in Patients (Pts) with Extensive Stage (ES) Small Cell Lung Cancer (SCLC).” Annals of Oncology, vol. 35, Sept. 2024, p. S1074. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.08.1903.

APA

Rudin, C. M., Salkeni, M. A., Gutierrez, M., Hayashi, H., Thompson, J., Arca, M., Hirose, D., Singh, J., Turner, J., Zhang, Y., & Owonikoko, T. K. (2024). 1812TiP IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC). Annals of Oncology, 35, S1074. https://doi.org/10.1016/j.annonc.2024.08.1903

Chicago

Rudin, C.M., M.A. Salkeni, M. Gutierrez, H. Hayashi, J. Thompson, M. Arca, D. Hirose, et al. 2024. “1812TiP IDeate-Lung03: A Phase Ib/II Study of Ifinatamab Deruxtecan (I-DXd) plus Atezolizumab (Atezo) with or without Carboplatin (Carbo) as First-Line (1L) Induction or Maintenance in Patients (Pts) with Extensive Stage (ES) Small Cell Lung Cancer (SCLC).” Annals of Oncology 35 (September): S1074. doi:10.1016/j.annonc.2024.08.1903.